Atrial Fibrillation review service
Atrial fibrillation is the most common heart rhythm disturbance and affects over 800,000 people in the UK.
Atrial fibrillation can affect adults of any age. However, it affects more men than women and becomes more common the older you get. It affects about 10% of people over 75.
Aspirin is still being widely prescribed to patients with atrial fibrillation when it offers no benefit and may even be harmful.
In 2014 just over a fifth of the UK population with atrial fibrillation – around 200,000 patients – were on aspirin, many of whom should be able to be switched onto anticoagulation therapy of some sort be it Warfarin or a NOAC (Rivaroxaban, Apixaban and Dabigatran).
In the old days aspirin was considered important for stroke prevention. New knowledge and reanalysis of prior studies reveals that aspirin does little to nothing to reduce stroke risk in this setting.
Stroke is the 3rd highest cause of death in England and a stroke allicts a person once every 5 minutes in the UK.
Ashburton pharmacists will:
- Review Atrial Fibrillation patients to ensure they're on the appropriate therapy. Eg transfer those patients being treated for Atrial Fibrillation with Aspirin onto an appropriate medication
- See those patients in clinics whose medicines may need changing. This will help practices to reduce potential risk of stroke in their patient population.
- Help practises to achieve the maximum number of QOF points available for Atrial Fibrillation (29)
- Transfer any poorly controlled Warfarin patients to NOAC's ensuring the correct patients are selected
- Pharma funding may be available to Ashburton via Pharmaceutical industry grants